Impact of p16 Status and Anatomical Site in Anti-PD-1 Immunotherapy-Treated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Patients

SIMPLE SUMMARY: Anti-PD-1 immunotherapies are approved for head and neck squamous cell carcinoma in the recurrent/metastatic setting, and utilization of these high-cost biologics is expected to increase as other indications are approved. Due to the high cost and selective response rate of these immu...

Descripción completa

Detalles Bibliográficos
Autores principales: Clancy, Kate, Hamill, Chelsea S., O’Neill, W. Quinn, Vu, Brandon, Thuener, Jason, Gui, Shanying, Li, Shawn, Fowler, Nicole, Rezaee, Rod, Lavertu, Pierre, Wasman, Jay, Patel, Monaliben, Shaikh, Hira, Vick, Eric, Madabhushi, Anant, Wise-Draper, Trisha M., Burkitt, Kyunghee, Teknos, Theodoros N., Pan, Quintin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8508514/
https://www.ncbi.nlm.nih.gov/pubmed/34638345
http://dx.doi.org/10.3390/cancers13194861

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8508514/
https://www.ncbi.nlm.nih.gov/pubmed/34638345
http://dx.doi.org/10.3390/cancers13194861

Ejemplares similares